Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Satellos BioscienceMSLE -2.14%37 Cash-to-Debt is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates MSLE with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,400 Biotechnology companies, Satellos Bioscience ranks better than 99.71% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Satellos Bioscience's cash to debt ratio for the quarter that ended in Mar. 2026 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Satellos Biosciencecould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Satellos Bioscience's Cash-to-Debt or its related term are showing as below:
MSLE'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66 Med: No Debt Max: No Debt
Current: No Debt
During the past 6 years, Satellos Bioscience's highest Cash to Debt Ratio was No Debt. The lowest was 0.66. And the median was No Debt.
MSLE's Cash-to-Debt is ranked better than 99.71% of 1400
companies
in the Biotechnology industry
Industry Median: 6.315
vs MSLE: No Debt
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Satellos Bioscience Cash-to-Debt Related Terms
Satellos Bioscience Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Satellos Bioscience's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Satellos Bioscience's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Satellos Bioscience Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Satellos Bioscience's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Satellos Bioscience's Cash-to-Debt falls into.
Satellos Bioscience's Cash to Debt Ratio for the fiscal year that ended in Dec. 2025 is calculated as:
Satellos Bioscience had no debt (1).
Satellos Bioscience's Cash to Debt Ratio for the quarter that ended in Mar. 2026 is calculated as:
Satellos Bioscience had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Satellos Bioscience (MSLE) has a Cash-to-Debt of No Debt (1) as of Mar. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Satellos Bioscience's Cash-to-Debt has ranged from 0.66 to 10,000.00. According to the industry distribution chart, Satellos Bioscience ranks #4 out of 1400 companies in the Biotechnology industry, placing it in the top 0.3%.
Is Satellos Bioscience's Cash-to-Debt too high?
Satellos Bioscience's current Cash-to-Debt of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 0.66 to a high of 10,000.00. Based on the distribution chart, Satellos Bioscience ranks #4 out of 1400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Satellos Bioscience has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Satellos Bioscience's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Satellos Bioscience ranks #4 out of 1400 companies for Cash-to-Debt. This places Satellos Bioscience in the top 0% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.32. Historically, Satellos Bioscience's own Cash-to-Debt has ranged from 0.66 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.32, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Satellos Bioscience's current Cash-to-Debt is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Satellos Bioscience stock overvalued right now?
Satellos Bioscience (MSLE) has a current Cash-to-Debt of No Debt (1). The current Cash-to-Debt is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Satellos Bioscience's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Satellos Bioscience (MSLE), the current Cash-to-Debt is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.
37GF Score
Get the complete analysis for MSLE
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MSLE has been successfully added to your 
